Opinion - (2025) Volume 12, Issue 4
Received: 01-Aug-2025, Manuscript No. ijn-26-183986;
Editor assigned: 04-Aug-2025, Pre QC No. P-183986;
Reviewed: 18-Aug-2025, QC No. Q-183986;
Revised: 22-Aug-2025, Manuscript No. R-183986;
Published:
29-Aug-2025
Citation: Ben-Ami, Yara. ”Pharmacology Enhances Neurorehabilitation: A Personalized Approach.” Int J Neurorehabilitation Eng 12 (2025):641.
Copyright: © 2025 Ben-Ami Y. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Pharmacological support is increasingly recognized as a vital component in enhancing neurorehabilitation, aiming to bolster the brain's intrinsic capacity for repair and functional recovery. This strategy complements traditional therapeutic interventions by targeting specific molecular pathways crucial for neuronal plasticity, synaptogenesis, and neuroprotection, thereby optimizing the brain's natural regenerative processes [1].
Within the scope of neurorehabilitation, certain classes of antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), have emerged as promising agents to facilitate motor recovery post-stroke. Their influence is believed to extend beyond mood regulation, potentially by upregulating neurotrophic factors and promoting synaptogenesis, thus amplifying the benefits of concurrent physical therapy [2].
Dopaminergic agents, exemplified by levodopa, are under active investigation for their potential to enhance motor learning and recovery across various neurological conditions, including Parkinson's disease and stroke. Research suggests that dopaminergic stimulation can prime the brain for plasticity during rehabilitation, leading to more enduring functional improvements [3].
Neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), are fundamental to neuronal survival, growth, and synaptic plasticity. Consequently, pharmacological interventions designed to elevate BDNF levels or mimic its actions are being explored as therapeutic avenues to promote recovery following neurological injury [4].
The inflammatory cascade triggered by neurological damage can significantly impede the recovery process. Consequently, anti-inflammatory agents, ranging from non-steroidal anti-inflammatory drugs (NSAIDs) to more targeted immunomodulators, are being examined for their capacity to mitigate these detrimental effects and foster a more conducive environment for neuroplasticity [5].
Excitotoxicity, driven by the excessive release of excitatory neurotransmitters like glutamate, represents a primary mechanism of secondary neuronal damage after acute brain injury. Medications designed to inhibit NMDA receptors or reduce glutamate release are being investigated as neuroprotective agents capable of improving recovery outcomes [6].
Amantadine, possessing both dopaminergic and NMDA receptor antagonist properties, has demonstrated efficacy in improving motor and cognitive functions in individuals with traumatic brain injury. Its application in neurorehabilitation is being studied for its potential to accelerate the recovery of gait, balance, and attention [7].
Stimulant medications, such as methylphenidate, are sometimes employed in neurorehabilitation protocols to address attention deficits and fatigue, common sequelae of acquired brain injury. The effectiveness of methylphenidate in enhancing cognitive and motor performance during rehabilitation is being evaluated, alongside its potential benefits and risks [8].
The optimal integration of pharmacological agents with specific rehabilitation techniques is paramount for achieving superior outcomes. This approach explores the synergistic potential of combining drug therapies with intensive physical or occupational therapy, underscoring the critical role of timing, dosage, and multimodal strategies in fostering neuroplasticity and functional recovery [9].
Personalized pharmacotherapy in neurorehabilitation hinges on a thorough understanding of individual patient needs, the specific characteristics of their injury, and their genetic makeup. The burgeoning field of precision medicine in neurorehabilitation aims to leverage pharmacogenomics and advanced diagnostics to guide medication selection and titration, thereby maximizing therapeutic effects and minimizing adverse reactions [10].
Pharmacological support in neurorehabilitation endeavors to enhance recovery by specifically targeting molecular pathways that are instrumental in neuronal plasticity, synaptogenesis, and neuroprotection. This approach serves to complement conventional therapies by augmenting the brain's inherent capacity for repair, thereby optimizing the functional outcomes for patients [1].
In the context of stroke rehabilitation, the utilization of antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), has shown considerable promise in accelerating motor recovery. The proposed mechanisms extend beyond mood modulation, suggesting a role in increasing neurotrophic factor expression and fostering synaptogenesis, which can amplify the positive effects of physical therapy interventions [2].
Dopaminergic agents, such as levodopa, are subjects of ongoing research for their capacity to improve motor learning and facilitate recovery in individuals with neurological conditions like Parkinson's disease and stroke. Investigations are exploring how dopaminergic stimulation can precondition the brain for enhanced plasticity during rehabilitation, leading to more sustained functional gains [3].
Neurotrophic factors, with brain-derived neurotrophic factor (BDNF) being a prime example, play a crucial role in supporting neuronal survival, promoting growth, and facilitating synaptic plasticity. Pharmacological strategies aimed at increasing endogenous BDNF levels or administering exogenous BDNF mimetics are being explored to encourage recovery after brain injury [4].
The inflammatory response that ensues after neurological injury can significantly impede the recovery process. Therefore, anti-inflammatory agents, encompassing both non-steroidal anti-inflammatory drugs (NSAIDs) and more targeted immunomodulatory compounds, are being investigated for their potential to mitigate these detrimental effects and create a more favorable environment for neuroplasticity [5].
Excitotoxicity, arising from the excessive release of excitatory neurotransmitters such as glutamate, is a major contributor to secondary neuronal damage following acute brain injury. Pharmacological agents designed to block NMDA receptors or diminish glutamate release are being explored as neuroprotective interventions that could potentially enhance recovery [6].
Amantadine, a medication with dual action as a dopamine agonist and NMDA receptor antagonist, has demonstrated efficacy in improving both motor and cognitive functions in patients who have sustained traumatic brain injuries. This review focuses on the evidence supporting amantadine's utility in neurorehabilitation, including its mechanisms of action and potential to expedite recovery in gait, balance, and attention [7].
Stimulant medications, exemplified by methylphenidate, are occasionally integrated into neurorehabilitation programs to address attention deficits and fatigue, which are frequently observed sequelae of acquired brain injury. This article critically appraises the effectiveness of methylphenidate in ameliorating cognitive and motor impairments in individuals undergoing rehabilitation, considering both its therapeutic benefits and potential adverse effects [8].
The synergistic potential of combining pharmacological interventions with specific rehabilitation techniques is a critical area of focus for optimizing patient outcomes. This paper delves into the combined effects of drug therapies and intensive physical or occupational therapy, emphasizing the importance of precisely timed administration, appropriate dosage, and the implementation of multimodal approaches to enhance neuroplasticity and facilitate functional recovery [9].
Precision medicine in neurorehabilitation necessitates a comprehensive understanding of each patient's unique needs, the specific characteristics of their injury, and their individual genetic profile. This emerging field aims to utilize pharmacogenomics and advanced diagnostic tools to guide the selection and precise titration of medications, thereby achieving optimal therapeutic responses and minimizing the occurrence of adverse reactions [10].
Pharmacological support plays a crucial role in neurorehabilitation by targeting molecular pathways to enhance neuronal plasticity, synaptogenesis, and neuroprotection, complementing traditional therapies. Key drug classes investigated include neurotransmitter modulators (dopaminergic, serotonergic agents), agents promoting neurotrophic factor release, anti-inflammatory drugs, and excitotoxicity blockers. Specific examples include SSRIs for motor recovery post-stroke, dopaminergic agents like levodopa for motor learning, neurotrophic factors such as BDNF, anti-inflammatory agents, NMDA receptor antagonists, amantadine, and stimulants like methylphenidate. The integration of these pharmacotherapies requires careful patient selection, personalized dosing, and close monitoring to maximize benefits and minimize side effects. Synergistic approaches combining pharmacotherapy with intensive rehabilitation and the principles of precision medicine, utilizing pharmacogenomics, are essential for tailoring interventions to individual patient needs and optimizing functional recovery.
None
None
International Journal of Neurorehabilitation received 1078 citations as per Google Scholar report
